Use of the Nuclear Matrix Protein 22 BladderChek Test for the Detection of Primary and Recurrent Urothelial Carcinoma

Table 1

Patient demographics.

Group	Median age; Year (25^th–75^th percentile)	Male; Number (%)
Primary UC ()	66 (59-75)	70 (68.0%)
Benign diseases ()	62 (52-72)	680 (60.4%)
value	<0.001^†	0.134^‡
^#
Primary UC ()	69 (59-77)	33 (68.8%)
Benign diseases ()	59 (46-71)	24 (57.1%)
value	0.002^†	0.254^‡
^&
Recurrent UC ()	75 (62-79)	21 (72.4%)
Nonrecurrent UC ()	64 (60-73)	38 (62.3%)
value	0.010^†	0.345^‡

Note: UC, urothelial carcinoma; patients performed the NMP22 BladderChek tests; ^#patients performed the NMP22 BladderChek tests and urine cytology tests; ^&patients with surgical treatment UC; ^†the Mann-Whitney test was used to calculate two-sided values; ^‡categorical variables were analyzed with a test.